SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
The Most Rousing Ladies Business visionaries of Today - 2Well known Tea Brands for Each Tea Sweetheart
- 3Taste the World: Five Food sources That Have Dazzled Worldwide Palates
- 4NASA unveils close-up pictures of the comet popping by from another star
- 5The pace of hiring just fell to the lowest since 2011, outside of the pandemic
- People can't get enough of this couple's Hallmark movie reviews. They don't know the painful backstory.
- Gaza amputees struggle to rebuild lives as the enclave faces shortages of prosthetic limbs
- Find Unexpected, yet invaluable treasure Excursion Rentals
- NASA set for first crewed moon return in over half a century
- Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder
- Desired Travel Objections Worldwide: Where to Go Straightaway
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Moderna to complete US mRNA manufacturing network with $140 million investment
- Exploring Programming Greatness: A Survey of \Easy to use Connection points\
